Significant benefits of Abbott's FreeStyle Libre System for people living with diabetes presented at ADA meeting. -Abbott.

Abbott announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle Libre system, the company's revolutionary continuous glucose monitor (CGM), and its impact on health outcomes across various patient populations and countries. These data were presented as part of multiple late-breaking abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Fla.

For the first time, a meta-analysis showed that using FreeStyle Libre system results in a meaningful decrease in HbA1c in a broad population of people with diabetes, including individuals with Type 1, Type 2 and of different ages. Several additional studies reaffirmed the ongoing health benefits that the FreeStyle Libre system provides. Also, a separate health economics analysis confirmed that use of the FreeStyle Libre system is associated with significant cost savings when compared to traditional blood glucose monitoring.

Expanded Real-World Evidence from 250,000+ Individuals Show Decrease in Glucose Variability and Improved Glucose. Control :. In 2017, Abbott released results from its first real-world data analysis of 50,000 FreeStyle Libre users across Europe , which showed that higher frequency of glucose monitoring with the FreeStyle Libre system correlated with improved glucose control and estimated HbA1c for people with diabetes . The new data, which included analyses generated from more than 250,000 individuals and more than 2.1 million sensors worldwide, further support those conclusions while also identifying additional positive outcomes, including: FreeStyle Libre system users scanned on average 13 times per day to check their glucose levels . Higher frequency scanners' time in hypoglycemia was 37 percent less compared to lower frequency scanners. On average, higher frequency scanners spent significantly less time in hypoglycemia during the day compared to lower frequency scanners (15.2 vs. 24.2 minutes/day). There was a similar pattern overnight with 12.7 to 19.0 minutes/night when comparing high frequency to lower frequency scanners. More frequent use of FreeStyle Libre system is associated with lower glucose variability . Data showed for the first time that increased testing with the FreeStyle Libre system was associated with decreased glucose variability with 34.5 percent vs. 40.6 percent in higher frequency vs. lower frequency scanners, respectively. High variability is associated with both increased hyperglycemia and hypoglycemia .The updated real-world findings were comprised of more than 2.2 billion glucose measurements and almost 300 million scans.

Additional Late-Breaking Abstracts> Further findings from the late-breaking abstracts at ADA demonstrated the following: 1.Significant Decrease in HbA1c Among a Broad Population: A meta-analysis found that use of the FreeStyle Libre system resulted in a substantial decrease in HbA1c, a test that shows the average glucose level over a period of time, with an absolute change of -0.56 percent. This is a clinically-meaningful decrease in HbA1c that may be associated with lower rates of diabetes-related health complications. 2.FreeStyle Libre System = Significant Cost Savings: Abbott also presented cost model data that showed significant savings when using the FreeStyle Libre system in the U.S. compared with routine self-monitoring of blood glucose (SMBG). The data showed those testing their glucose six times per day with FreeStyle Libre system can save more than $120 a month compared to the cost of six test strips per day. This has the potential to increase to $290 a month for people testing 10 times per day. The ADA recommends testing blood glucose six to ten times per day for certain insulin-using populations. 3.Teenagers and Young Adult Populations Improved Time in Range: Additional analysis of two previously reported clinical studies in Europe--IMPACT6 (2016) and SELFY7 (2017) --evaluated the FreeStyle Libre system as a replacement for SMBG and examined outcomes in patients aged 13-24 years old8. Both studies demonstrated improvements in glycemic control in the teenager and young adult age groups -- two groups that are known to have significant challenges with glycemic control during this transitional period. Teenagers in the SELFY study significantly improved time in range by 1.2�2.5 hours/day and significantly improved their HbA1c. This is one of the first studies to demonstrate the benefits of continuous glucose monitoring in these age groups.

Comment:The FreeStyle Libre system is now being used by more than 650,000 people across more than 42 countries. Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 28 countries, including France , Ireland , Japan , the United Kingdom , and the U.S.